Zumutor is a leading Immuno-Oncology company in the space of targeted NK cell therapeutics. Our proprietary Human Antibody platform INABLR ™ is the genesis to our wholly owned, first-in-class therapeutic antibodies which target innate immunity and regulate the tumor micro environment.
Formed in 2013, we are headquartered at CIC Cambridge Campus, 1 Broadway, Cambridge, MA, USA and an ISO 9001:2015 laboratory in Bangalore, India.
Our key drivers to success include a platform approach to novel therapeutics, an experienced Antibody engineering team, global advisors and investors.
